PeptideFactSheetsAn independent reference
Menu

Adamantane-derived research drug · Fact sheet

Bromantane

Also known as Bromantan · Ladasten

Bromantane is an adamantane derivative studied for asthenia, meaning persistent weakness or fatigue. Regional human reports and animal dopamine findings do not establish a broadly effective stimulant or cognitive enhancer.

Not FDA approvedEarly human evidence
Brain, mood & sleep

What is Bromantane?

It is a small molecule, not a peptide. Ladasten is a name used in the Russian clinical literature.

Effects on dopamine synthesis in rats do not establish the same functional or safety effects in humans.

Benefits & claims

Readers encounter Bromantane in discussions of cognition, mood or mental fatigue. The relevant study population and outcome determine whether those claims are supported.

What the evidence supports

  • The multicenter report described symptom improvement during 28 days of treatment.
  • Without an adequate concurrent control, expectancy, natural recovery and other treatment effects remain alternatives.
  • Rodent synaptic-plasticity findings cannot establish durable human motivation or addiction-recovery benefit.
Research areas
  • Cognition and memory
  • Neurologic or psychiatric research

Dosage & frequency

No established human regimen

The reviewed sources do not establish a human treatment amount or frequency for Bromantane. Animal and laboratory exposures are not human regimens.

How to read these amounts

An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.

Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences

Formulations, interactions & practical context

Formulation differences

  • Effects on dopamine synthesis in rats do not establish the same functional or safety effects in humans.

Interactions & precautions

  • The reviewed sources do not establish a comprehensive human interaction profile for this exact substance or combination.

What is still unresolved

  • Reproducible benefit on everyday function in the intended population
  • Long-term safety and clinically important interactions
  • Equivalence of nonstandard products to research formulations
[Treatment of asthenic disorders in patients with psychoautonomic syndrome: results of a multicenter study on efficacy and safety of ladasten]. [Ladasten versus placebo effect self-evaluated by neurasthenia patients with different EEG alpha rhythm types]. The effects of ladasten on dopaminergic neurotransmission and hippocampal synaptic plasticity in rats.

Side effects & risks

  • The short clinical report described adverse effects and some discontinuations; it cannot determine uncommon or long-term harms.
  • Human interaction data and safety of nonstandard intranasal preparations are inadequately established.

This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.

Clinical research

Early human evidence

A multicenter report analyzed 728 people with asthenic disorders but lacked a randomized comparator in the indexed description. A separate placebo-related analysis highlights subjective and baseline differences.

Studies

Personal experiences

Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.

Explore 2 sourced accounts by reported effect.

Energy: reported experiences

Mixed account · personal report

More drive, but insomnia, irritability and reduced sexual interest

Another author described more energy and focus during six days of bromantane, alongside sleeping only three to four hours, irritability and reduced sexual interest. Sleep improved after discontinuation, while agitation and sexual symptoms were still resolving.

Reported use in this account

Product
Bromantane
Amount
25 mg
Frequency
Morning use around 8 a.m. as described
Route
Oral
Duration
Six days

The author described low baseline libido and supplied no clinical assessment. The account cannot establish a hormonal mechanism or a typical risk rate.

Read the original account

Approval status

Bromantane is not an FDA-approved treatment for the cognitive or mood uses discussed here. Regional use, historical trials and online availability are separate from U.S. drug approval.

No FDA-approved product for this entry

Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.

Open questions

  • Reproducible benefit on everyday function in the intended population
  • Long-term safety and clinically important interactions
  • Equivalence of nonstandard products to research formulations

Summary

Rodent synaptic-plasticity findings cannot establish durable human motivation or addiction-recovery benefit.

Sources

Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.

  2. pubmed[Ladasten versus placebo effect self-evaluated by neurasthenia patients with different EEG alpha rhythm types].

    Clinical analysis of subjective and placebo effects in neurasthenia.

How we assess sources · Suggest a correction